SCHEMBL4842001

SCHEMBL4842001

COc1ccc2c(-c3ccc(OC)c(OC)c3)n[nH]c(=O)c2c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 3/20 0.73
PDE4B Q07343 3/20 0.73
PDE4C Q08493 3/20 0.73
PDE4D Q08499 3/20 0.73
ENPP1 P22413 2/20 0.57
GSK3A P49840 2/20 0.51
GSK3B P49841 2/20 0.51
DYRK1A Q13627 2/20 0.51
MAPT P10636 3/20 0.50
KDM4E B2RXH2 2/20 0.50
LMNA P02545 1/20 0.50
TSHR P16473 1/20 0.50
ALOX12 P18054 1/20 0.50
MAPK1 P28482 1/20 0.50
HSD17B10 Q99714 1/20 0.50
ABCB1 P08183 2/20 0.49
PRMT5 O14744 1/20 0.47
WDR77 Q9BQA1 1/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4124300 0.87 ENPP1 (0.66) PDE4APDE4BPDE4CPDE4DENPP1
SCHEMBL4833870 0.85 PDE4B (0.52) PDE4APDE4BPDE4CPDE4DENPP1
SCHEMBL6477699 0.85 PDE4A (1.00) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL4840424 0.84 ENPP1 (0.57) PDE4APDE4BPDE4CPDE4DENPP1
SCHEMBL4838570 0.83 ENPP1 (0.56) PDE4APDE4BPDE4CPDE4DENPP1
SCHEMBL4844032 0.83 ENPP1 (0.62) PDE4APDE4BPDE4CPDE4DENPP1
SCHEMBL4834510 0.83 ENPP1 (0.58) PDE4APDE4BPDE4CPDE4DENPP1
SCHEMBL4841875 0.82 ENPP1 (0.61) PDE4APDE4BPDE4CPDE4DENPP1
SCHEMBL15897891 0.82 ENPP1 (0.64) PDE4APDE4BPDE4CPDE4DENPP1
SCHEMBL4833909 0.82 ENPP1 (0.61) PDE4APDE4BPDE4CPDE4DENPP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423030-B2 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof SANOFI-AVENTIS (FR) 2008-09-09 US disclosed
EP-1737840-B1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-09-12 EP disclosed
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-05-03 US disclosed
EP-1737840-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-01-03 EP disclosed
WO-2005103033-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099895-A1 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF CYP11B2, CYP11B1, GOT2 PDE4A 1615/4885PDE4B 1845/4885PDE4C 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.